TITLE

The Effect of Tar and Ultraviolet on the Skin

AUTHOR(S)
Comaish, James Stanley
PUB. DATE
March 1987
SOURCE
Journal of Investigative Dermatology;Mar87 Supplement, Vol. 88, p61s
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In Newcastle upon Tyne, the department of dermatology has found that one researcher's dithranol regime to be faster in clearing psoriasis than another's tar treatment. Because of dithranol, corticosteroids, methotrexate and more recently, PUVA therapy, a whole generation of dermatologists is growing up who do not use tar, because they do not understand the indications and limitations of tar therapy. The effect of tar on normal epidermis has been examined by a number of workers. There is some controversy as to whether tar stimulates or suppress growth.
ACCESSION #
12468958

 

Related Articles

  • PRESCRIBING ANALYSIS OF CORTICOSTEROIDS AMONG THE DERMATOLOGY IN-PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL, KARAIKAL, PUDUCHERRY. A PROSPECTIVE OBSERVATIONAL STUDY. DIVYASHANTHI, C. M.; MANIVANNAN, E. // International Journal of Pharma & Bio Sciences;Apr2014, Vol. 5 Issue 2, pP-324 

    Corticosteroids remain the most important and frequently prescribed drugs for cutaneous diseases. This study is an effort to assess the drug prescribing patterns of corticosteroids for various skin diseases, to analyse the rationale behind and also to affirm the physicians' adherence to dosages...

  • Critical Considerations on Optimizing Topical Corticosteroid Therapy. Hougeir, Firas George; Cook-Bolden, Fran E.; Rodriguez, David; Berlin, Joshua M. // Journal of Clinical & Aesthetic Dermatology;2015 Supplement 1, Vol. 8, pS3 

    The article focuses on some points to be considered for effective topical corticostrroid therapy. It is noted that disease severity and distribution should be considered by dermatologists selecting a topical corticosteroid. It is mentioned that information in terms of the treatment timeline and...

  • Methotrexate in systemic lupus erythematosus. Wong, J.M.; Esdaile, J.M. // Lupus;2005, Vol. 14 Issue 2, p101 

    The most appropriate treatment of moderate, nonorgan threatening disease activity in systemic lupus erythematosus (SLE) remains poorly defined, although methotrexate (MTX) is commonly used. The results of 20 uncontrolled case series and a single retrospective cohort study tend to support its use...

  • Psoriasiform Drug Eruption due to Abatacept. Kato, Kohei; Satoh, Takahiro; Nishizawa, Aya; Yokozeki, Hiroo // Acta Dermato-Venereologica;2011, Vol. 91 Issue 3, p362 

    The article presents a case study of a 59-year-old woman who was presented with a 4-month history of erythematous plaques on her palms and extremities. She was diagnosed with rheumatoid arthritis (RA) with a long-term history of using methotrexate and oral prednisolone. The patient was treated...

  • Fresh from the pipeline: Efalizumab. Marecki, Sylvia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jun2004, Vol. 3 Issue 6, p473 

    Efalizumab (Raptiva; Genentech/Xoma/Serono) is a monoclonal antibody that binds to CD11a, a cell-surface protein that has a key role in the pathological immune response in the skin disorder psoriasis. Following its approval by the FDA in October 2003 for the treatment of moderate-to-severe...

  • Methotrexate Inhibits the Human C5a-Induced Skin Response in Patients With Psoriasis. Ternowitz, Thomas; Bjerring, Peter; Andersen, Peter H.; Schröder, Jens-M.; Kragballe, Knud // Journal of Investigative Dermatology;Aug87, Vol. 89 Issue 2, p192 

    In this study we examined the effects of intradermal injections of human complement split product C5a in 10 patients with psoriasis in long-term treatment with methotrexate (MTX). The C5a was injected at the end of the weekly MTX cycle just before the intake of the first MTX dose and 3 h after...

  • SELECTIVE ACTION OF METHOTREXATE ON PSORIATIC EPIDERMAL CELLS. Weinstein, Gerald D.; Velasco, Joseph // Journal of Investigative Dermatology;Jul72, Vol. 59 Issue 1, p121 

    Rapidly proliferating tumors respond to cancer chemotherapeutic agents like methotrexate (MTX) because more tumor cells than normal cells are in the drug-sensitive synthesis (S) phase during exposure to the drug. Evidence is presented that not only more psoriatic cells, like tumor cells, are in...

  • Dermatological pharmacology: topical agents. Chowdhury, Mahbub M. U. // Africa Health;May2014, Vol. 36 Issue 4, p41 

    Topical therapies constitute an important aspect of dermatological treatments. This article covers the principles of topical treatments, vehicles used and a number of commonly used topical agents, including corticosteroids. Indications for use and common adverse effects of these topical agents...

  • Rituxan shows promise as rheumatoid arthritis treatment.  // PharmaWatch: Biotechnology;August 2004, Vol. 3 Issue 8, p9 

    Biogen Idec Inc. and Roche Inc. have published the results of a phase IIa study showing that two doses of Rituxan, administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis for up to 48 weeks when combined with methotrexate (MTX), compared to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics